Yihong Li

Prof. Yihong Li

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2016 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
YSYuanhui Song
Yuanhui Song
Yihong LiYihong Li
Yihong Li
QXQien Xu
Qien Xu
ZLZhe Liu
Zhe Liu
Mesoporous silica nanoparticles for stimuli-responsive controlled drug delivery: advances, challenges, and outlook Yuanhui Song, Yihong Li, Qien Xu, Zhe Liu Wenzhou Institute of Biomaterials and Engineering (WIBE), Wenzhou Medical University, Wenzhou, Zhejiang, People’s Republic of China With the development of nanotechnology, the application of nanomaterials in the field of drug delivery has attracted much attention in the past decades. Mesoporous silica nanoparticles as promising drug nanocarriers have become a new area of interest in recent years due to their unique properties and capabilities to efficiently entrap cargo molecules. This review describes the latest advances on the application of mesoporous silica nanoparticles in drug delivery. In particular, we focus on the stimuli-responsive controlled release systems that are able to respond to intracellular environmental changes, such as pH, ATP, GSH, enzyme, glucose, and H2O2. Moreover, drug delivery induced by exogenous stimuli including temperature, light, magnetic field, ultrasound, and electricity is also summarized. These advanced technologies demonstrate current challenges, and provide a bright future for precision diagnosis and treatment. Keywords: mesoporous silica nanoparticle, drug delivery system, controlled release, stimuli-responsive, chemotherapy

9 December 2019 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
Weishan WangWeishan Wang
Weishan Wang
Shanshan LiShanshan Li
Shanshan Li
ZLZilong Li
Zilong Li
JZJingyu Zhang
Jingyu Zhang
KFKeqiang Fan
Keqiang Fan
LZLixin Zhang
Lixin Zhang

6 May 2016 in ACS Synthetic Biology
Verified
Journal Article
Closed access
WWWeishan Wang
Weishan Wang
TYTongjian Yang
Tongjian Yang
Yihong LiYihong Li
Yihong Li
SLShanshan Li
Shanshan Li
SYShouliang Yin
Shouliang Yin
KYKeqian Yang
Keqian Yang

25 February 2021 in Science China Chemistry
Verified
Journal Article
Closed access
PDF file
CZChen Zhang
Chen Zhang
Yihong LiYihong Li
Yihong Li
XMXinyong Ma
Xinyong Ma
WHWenxin He
Wenxin He
CLChenxi Liu
Chenxi Liu
ZLZhe Liu
Zhe Liu

11 November 2016 in Analytical Chemistry
Verified
Journal Article
Closed access
ZLZhe Liu
Zhe Liu
WCWaner Chen
Waner Chen
Yihong LiYihong Li
Yihong Li
QXQien Xu
Qien Xu

6 March 2024 in Biomolecules
Verified
Journal Article
Open access
PDF file
Yihong LiYihong Li
Yihong Li
CZChenglong Zhou
Chenglong Zhou
HLHuina Liu
Huina Liu
TCTing Cai
Ting Cai
Huadong FanHuadong Fan
Huadong Fan
A growing number of studies have indicated that extracellular vesicles (EVs), such as exosomes, are involved in the development of neurodegenerative diseases. Components of EVs with biological effects like proteins, nucleic acids, or other molecules can be delivered to recipient cells to mediate physio-/pathological processes. For instance, some aggregate-prone proteins, such as β-amyloid and α-synuclein, had been found to propagate through exosomes. Therefore, either an increase of detrimental molecules or a decrease of beneficial molecules enwrapped in EVs may fully or partly indicate disease progression. Numerous studies have demonstrated that dysbiosis of the gut microbiota and neurodegeneration are tightly correlated, well-known as the “gut–brain axis”. Accumulating evidence has revealed that the gut bacteria-derived EVs play a pivotal role in mediating microbe–host interactions and affect the function of the “gut–brain axis”, which subsequently contributes to the pathogenesis of neurodegenerative diseases. In this review, we first briefly discuss the role of EVs from mammalian cells and microbes in mediating the progression of neurodegenerative diseases, and then propose a novel strategy that employs EVs of plants (plant cell-derived exosome-like nanoparticles) for treating neurodegeneration.